Cargando…

Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers

Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months af...

Descripción completa

Detalles Bibliográficos
Autores principales: Algarate, Sonia, Serrano, Laura, Bueno, Jessica, Herrero-Cortina, Beatriz, Alvarado, Elena, González-Barriga, María T., Ducons, María, Montero-Marco, Jesica, Arnal, Sara, Acha, Beatriz, Riesgo, María, Taboada, Ana, Sanz-Burillo, Pilar, Yuste, Cristina, Benito, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341794/
https://www.ncbi.nlm.nih.gov/pubmed/37445893
http://dx.doi.org/10.3390/ijms241310713
_version_ 1785072346632028160
author Algarate, Sonia
Serrano, Laura
Bueno, Jessica
Herrero-Cortina, Beatriz
Alvarado, Elena
González-Barriga, María T.
Ducons, María
Montero-Marco, Jesica
Arnal, Sara
Acha, Beatriz
Riesgo, María
Taboada, Ana
Sanz-Burillo, Pilar
Yuste, Cristina
Benito, Rafael
author_facet Algarate, Sonia
Serrano, Laura
Bueno, Jessica
Herrero-Cortina, Beatriz
Alvarado, Elena
González-Barriga, María T.
Ducons, María
Montero-Marco, Jesica
Arnal, Sara
Acha, Beatriz
Riesgo, María
Taboada, Ana
Sanz-Burillo, Pilar
Yuste, Cristina
Benito, Rafael
author_sort Algarate, Sonia
collection PubMed
description Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.
format Online
Article
Text
id pubmed-10341794
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103417942023-07-14 Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers Algarate, Sonia Serrano, Laura Bueno, Jessica Herrero-Cortina, Beatriz Alvarado, Elena González-Barriga, María T. Ducons, María Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, María Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael Int J Mol Sci Brief Report Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines. MDPI 2023-06-27 /pmc/articles/PMC10341794/ /pubmed/37445893 http://dx.doi.org/10.3390/ijms241310713 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Algarate, Sonia
Serrano, Laura
Bueno, Jessica
Herrero-Cortina, Beatriz
Alvarado, Elena
González-Barriga, María T.
Ducons, María
Montero-Marco, Jesica
Arnal, Sara
Acha, Beatriz
Riesgo, María
Taboada, Ana
Sanz-Burillo, Pilar
Yuste, Cristina
Benito, Rafael
Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title_full Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title_fullStr Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title_full_unstemmed Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title_short Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
title_sort persistence of anti-s1 igg against sars-cov-2 eight months after the booster dose of vaccine in naive and previously infected healthcare workers
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341794/
https://www.ncbi.nlm.nih.gov/pubmed/37445893
http://dx.doi.org/10.3390/ijms241310713
work_keys_str_mv AT algaratesonia persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT serranolaura persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT buenojessica persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT herrerocortinabeatriz persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT alvaradoelena persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT gonzalezbarrigamariat persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT duconsmaria persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT monteromarcojesica persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT arnalsara persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT achabeatriz persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT riesgomaria persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT taboadaana persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT sanzburillopilar persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT yustecristina persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT benitorafael persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers
AT persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers